

Endocannabinoid System Pharmacology: Therapeutic Promise and Clinical Pitfalls

R.E. Ugandar^{1*}, Sabeen Fatma², Sweety Lanjhiana³, Sukamal Das⁴, Annu Sharma⁵

¹Santhiram College of Pharmacy, Nandyal-518501, Andhra Pradesh, India

²Department of Biotechnology, Chaudhary Charan Singh University, Meerut, Uttar Pradesh, India

³Institute of Pharmaceutical Studies, Sakri, Bilaspur -495001, (CG)

⁴Bidyanagar, Mahura, Janla, Bhubaneswar, Odisha 752054, Pin- 752054

⁵Shobhit University, Gangoh (U.P), 247341, India

*Corresponding Author E-mail: reugandar@gmail.com

Abstract:

The endocannabinoid system (ECS) has emerged as one of the most intriguing and therapeutically promising signaling networks in modern pharmacology. Comprising endogenous cannabinoids, G-protein coupled receptors, and metabolic enzymes, the ECS regulates an array of physiological processes including pain modulation, mood regulation, appetite, inflammation, and neuroprotection. Pharmacological modulation of this system offers immense therapeutic potential for disorders ranging from chronic pain and epilepsy to metabolic syndrome and neurodegenerative diseases. However, despite its promise, clinical translation has been impeded by significant safety concerns, complex receptor interactions, and unpredictable psychotropic effects. This review provides a comprehensive overview of the molecular pharmacology of the ECS, its therapeutic targets, and the challenges that hinder clinical application. Emphasis is placed on recent drug development efforts, translational hurdles, and future perspectives for safely harnessing the ECS in medicine.

Keywords: Endocannabinoid system, CB1 receptor, CB2 receptor, Anandamide, 2-AG, Cannabinoid pharmacology, Therapeutic targets, Clinical challenges

Received: Jan. 14, 2026

Revised: Feb. 18, 2026

Accepted: March. 15, 2026

Published: April 10, 2025

DOI: <https://doi.org/10.64474/3107-6726.Vol2.Issue1.2>

<https://jepmr.nknpub.com/1/issue/archive>

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

1. Introduction

The endocannabinoid system (ECS) is a remarkably intricate neuromodulatory network that serves as a master regulator of physiological homeostasis. It influences a wide range of biological functions, including mood, pain perception, appetite, memory, immune response, and energy metabolism. Since the isolation of Δ^9 -tetrahydrocannabinol (THC)—the primary

psychoactive component of *Cannabis sativa*—and the subsequent discovery of endogenous cannabinoids such as anandamide and 2-arachidonoylglycerol (2-AG), scientific interest in the ECS has grown exponentially¹⁻². What began as a curiosity in neurochemistry has evolved into one of the most dynamic and promising areas of modern pharmacology, offering new insights into both normal physiology and disease mechanisms.

The ECS operates through a finely tuned network of cannabinoid receptors (primarily CB1 and CB2), endogenous ligands (endocannabinoids), and metabolic enzymes that synthesize and degrade these ligands³. This system exerts its effects across multiple organ systems, making it a key player in regulating neural signaling, cardiovascular tone, immune modulation, and metabolic balance. Because of this broad physiological influence, the ECS presents an attractive target for therapeutic interventions in conditions such as chronic pain, neurodegenerative diseases, obesity, inflammation, and even cancer⁴.

However, the clinical translation of ECS-based therapies has proven to be far more complicated than initially expected. While early enthusiasm surrounded compounds like the CB1 receptor antagonist rimonabant—once considered a revolutionary anti-obesity medication—its withdrawal due to severe psychiatric side effects, including depression and anxiety, underscored the delicate balance of modulating this system⁵⁻⁶. Similarly, although cannabidiol (CBD) has achieved notable regulatory approval for specific conditions like refractory epilepsy, its broader therapeutic applications remain under scrutiny due to inconsistent efficacy and limited clinical data.

This paradox—where immense therapeutic potential coexists with significant clinical risk—defines the present landscape of endocannabinoid pharmacology. Understanding the intricate mechanisms governing the ECS, along with the reasons behind past pharmacological failures, is essential for harnessing its full therapeutic value while minimizing adverse outcomes⁷⁻⁸.

2. Components of the Endocannabinoid System

The endocannabinoid system (ECS) is a finely coordinated biochemical network composed of three major components: endogenous cannabinoids (endocannabinoids), cannabinoid receptors, and the enzymes responsible for their synthesis and degradation⁹⁻¹⁰. Together, these elements form a signaling system that dynamically modulates physiological processes throughout the body. Unlike classical neurotransmitters that are stored in vesicles and released in response to an electrical impulse, endocannabinoids are produced “on demand” in response to specific physiological stimuli, allowing for rapid and localized control of cellular activity.

2.1. Endocannabinoids

The two best-characterized endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG), both derived from membrane lipid precursors. Anandamide, discovered in 1992, was named after the Sanskrit word *ananda*, meaning “bliss,” reflecting its role in modulating mood and emotional balance. It acts as a partial agonist at both CB1 and

CB2 receptors, though it displays higher affinity for CB1, making it particularly important in central nervous system signaling. Anandamide is rapidly degraded by the enzyme fatty acid amide hydrolase (FAAH), which terminates its activity and ensures precise temporal control over receptor stimulation¹¹⁻¹².

In contrast, 2-AG, identified in 1995, serves as a full agonist at both CB1 and CB2 receptors, exerting more robust signaling effects across both neural and peripheral tissues. It is primarily hydrolyzed by monoacylglycerol lipase (MAGL), which, like FAAH, plays a key role in signal termination. Both anandamide and 2-AG are lipid-based signaling molecules that differ significantly from traditional neurotransmitters—not only in their synthesis and degradation but also in their mechanism of release and reuptake. Their “on-demand” biosynthesis enables a highly adaptive and context-specific mode of communication between cells, contributing to the ECS’s versatility in maintaining homeostasis¹³⁻¹⁴.

2.2. Cannabinoid Receptors

Endocannabinoids exert their effects primarily through two G-protein-coupled receptor subtypes: CB1 and CB2.

- ❖ CB1 receptors are widely distributed throughout the central nervous system (CNS), especially in regions such as the hippocampus, cerebellum, and basal ganglia. They are primarily involved in modulating synaptic transmission, where activation leads to the inhibition of neurotransmitter release (e.g., glutamate, GABA, dopamine) through Gi/o-protein signaling pathways. This mechanism underlies many of the psychoactive and neuroprotective effects of cannabinoids, including their influence on cognition, motor control, and pain perception¹⁵.
- ❖ CB2 receptors, on the other hand, are predominantly expressed in immune cells and peripheral tissues. Their activation regulates immune cell migration, cytokine release, and inflammatory responses. CB2 receptor modulation has therefore emerged as a promising therapeutic strategy for inflammatory and autoimmune diseases without the psychotropic effects associated with CB1 activation¹⁶.

In addition to these canonical receptors, emerging research has identified several non-classical cannabinoid targets, including GPR55, TRPV1 (transient receptor potential vanilloid type 1), and PPAR γ (peroxisome proliferator-activated receptor gamma). These receptors contribute to the broader pharmacological complexity of the ECS, mediating diverse physiological outcomes beyond traditional cannabinoid signaling¹⁷.

2.3. Metabolic Enzymes

The third essential component of the ECS is the enzymatic machinery responsible for endocannabinoid biosynthesis and degradation. For anandamide, synthesis is primarily catalyzed by N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD), while

diacylglycerol lipase (DAGL α and DAGL β) enzymes drive the production of 2-AG. Once released and bound to their respective receptors, these endocannabinoids are rapidly broken down to prevent overstimulation. The enzymes FAAH and MAGL serve as the primary catabolic regulators for anandamide and 2-AG, respectively, ensuring precise control of signaling duration and intensity¹⁸.

This tight enzymatic regulation maintains the delicate balance of endocannabinoid activity essential for homeostasis. Dysregulation of these pathways—whether through excessive synthesis, impaired degradation, or altered receptor sensitivity—can disrupt normal physiological function, contributing to disorders such as chronic pain, obesity, anxiety, and neurodegeneration. Thus, understanding the interplay between these three components—endocannabinoids, receptors, and metabolic enzymes—is fundamental for developing safe and effective ECS-targeted therapies¹⁹⁻²⁰.

3. Molecular Pharmacology and Signaling Pathways

At the molecular level, the pharmacology of the endocannabinoid system (ECS) is primarily mediated through G-protein-coupled receptor (GPCR) signaling. Both CB1 and CB2 receptors belong to the Gi/o-coupled GPCR family, meaning that upon activation, they inhibit adenylyl cyclase, the enzyme responsible for converting ATP into cyclic AMP (cAMP). This inhibition leads to a decrease in intracellular cAMP levels, thereby modulating downstream signaling cascades that control neuronal excitability and synaptic activity²¹⁻²².

In neurons, CB1 receptor activation has profound electrophysiological consequences. It leads to the closure of voltage-gated calcium channels (VGCCs) and the opening of inwardly rectifying potassium channels (GIRKs). These changes reduce calcium influx and increase potassium efflux, resulting in hyperpolarization of the neuronal membrane. The net effect is a reduction in neurotransmitter release, effectively dampening synaptic transmission. This mechanism underlies the well-known ability of cannabinoids to modulate pain, anxiety, motor coordination, and memory²³⁻²⁴. By contrast, excessive or prolonged CB1 receptor activation—such as that seen with high doses of THC—can disrupt normal synaptic signaling and impair cognitive function, including attention, learning, and short-term memory.

Beyond these immediate ion channel effects, cannabinoid receptor signaling extends deeply into intracellular pathways that regulate gene expression, cell growth, and survival. Both CB1 and CB2 receptors can modulate several major signaling cascades, including the mitogen-activated protein kinase (MAPK) pathway, the phosphoinositide 3-kinase (PI3K)-Akt pathway, and the extracellular signal-regulated kinase (ERK1/2) pathway²⁵⁻²⁶. Through these mechanisms, ECS activation can influence neuroplasticity, apoptosis, cell proliferation, and metabolic regulation, linking cannabinoid signaling to broader physiological and pathological processes.

Importantly, the two cannabinoid receptors differ significantly in their functional outcomes. CB1 receptor activation in the central nervous system is primarily associated with neuromodulatory effects—including analgesia, mood alteration, and appetite regulation—but its overactivation can lead to adverse consequences such as cognitive impairment, dependency, and psychomotor dysfunction²⁷. In contrast, CB2 receptor activation, mainly occurring in immune and peripheral tissues, tends to elicit anti-inflammatory and cytoprotective effects. These include the suppression of pro-inflammatory cytokine release, reduction of oxidative stress, and promotion of tissue repair mechanisms. As such, CB2-selective agonists are currently being explored for therapeutic potential in autoimmune diseases, neuroinflammation, and neurodegenerative disorders such as Alzheimer's and Parkinson's disease (Figure 1)²⁸⁻²⁹.

Overall, the molecular pharmacology of the ECS exemplifies a fine-tuned balance between neural inhibition and cellular protection. While CB1-driven signaling is more closely tied to psychoactive and neural effects, CB2-mediated pathways offer a non-psychoactive therapeutic avenue, representing one of the most promising frontiers in modern cannabinoid pharmacology³⁰.

5. Clinical Pitfalls and Safety Concerns

While the endocannabinoid system (ECS) represents one of the most promising therapeutic frontiers in modern pharmacology, translating its preclinical success into safe and effective clinical outcomes has proven to be a formidable challenge. The pharmacological complexity of cannabinoids—along with their psychoactivity, pharmacokinetic variability, and social stigma—creates a multifaceted set of obstacles that limit their widespread medical adoption³¹.

1. Psychoactive Effects:

One of the foremost safety concerns in cannabinoid pharmacotherapy arises from CB1 receptor activation within the central nervous system. Stimulation of these receptors, particularly by compounds such as Δ^9 -tetrahydrocannabinol (THC), can result in cognitive impairment, altered perception, anxiety, and even psychosis-like symptoms in vulnerable individuals³²⁻³³. While these psychoactive effects may be desirable in recreational contexts, they pose serious challenges for medical use, particularly in chronic conditions requiring long-term treatment. This has prompted a growing shift toward non-psychoactive alternatives, such as cannabidiol (CBD) or peripherally restricted CB1 antagonists, to mitigate central nervous system side effects.

2. Tolerance and Dependence:

Chronic exposure to cannabinoids leads to receptor desensitization and downregulation, resulting in tolerance—a reduced therapeutic response over time that necessitates higher doses to achieve the same effect. Additionally, abrupt discontinuation after

prolonged use can trigger withdrawal symptoms, including irritability, insomnia, and anxiety. These issues raise legitimate concerns about dependence potential, particularly with THC-rich formulations or long-term use of synthetic cannabinoids³⁴⁻³⁵. Balancing therapeutic efficacy while avoiding tolerance remains an ongoing pharmacological challenge.

3. Complex Pharmacokinetics:

Cannabinoids exhibit high lipophilicity, allowing them to accumulate in fatty tissues and exhibit prolonged half-lives. This property, coupled with variable oral bioavailability due to extensive first-pass metabolism, complicates dose optimization and therapeutic monitoring. Moreover, factors such as individual metabolic rate, body fat content, and route of administration (oral, sublingual, inhalation) significantly influence pharmacokinetic behavior. Such variability makes achieving consistent plasma concentrations difficult, posing hurdles for standardized clinical dosing and regulatory approval³⁶⁻³⁷.

4. Drug–Drug Interactions:

Cannabinoids also have the potential to interfere with cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2C9, which are crucial for the metabolism of many commonly prescribed drugs. This interaction can enhance or inhibit the metabolism of co-administered medications, leading to altered drug efficacy or toxicity. For instance, patients taking anticoagulants, antiepileptics, or antidepressants may experience significant pharmacokinetic interactions when concurrently using cannabinoid-based therapies³⁸⁻³⁹. Therefore, clinicians must exercise caution and closely monitor potential adverse pharmacological synergies.

5. Regulatory Barriers and Social Stigma:

Despite the growing body of scientific evidence supporting therapeutic cannabinoid use, regulatory and social challenges persist. The historical association of cannabis with recreational drug use has fostered a stigma that continues to impede research funding, clinical trial approval, and physician acceptance⁴⁰. Moreover, inconsistent legal frameworks across countries—and even within regions—complicate the standardization, manufacturing, and prescription of cannabinoid-based medicines. These barriers not only delay drug development but also contribute to significant disparities in patient access⁴¹.

The rimonabant episode serves as a cautionary tale of the clinical pitfalls associated with ECS modulation. Initially heralded as a groundbreaking anti-obesity agent, rimonabant—a centrally acting CB1 receptor antagonist—demonstrated impressive metabolic benefits in early trials. However, its use was soon linked to severe psychiatric side effects, including depression, anxiety, and suicidal ideation, ultimately leading to its global market withdrawal. This event underscored the critical importance of selective receptor targeting and CNS-sparing strategies in cannabinoid drug development⁴².

In essence, while the ECS holds immense therapeutic promise, its clinical manipulation demands extreme pharmacological precision and caution. Overcoming these safety and regulatory hurdles will require the development of receptor-specific, non-psychoactive compounds, improved pharmacokinetic profiling, and a more supportive global regulatory environment to fully realize the medical potential of cannabinoid-based therapies ⁴³.

6. Emerging Trends and Future Directions

Contemporary cannabinoid pharmacology is rapidly evolving toward more selective, precise, and safer therapeutic strategies. After decades of trial and error—marked by both scientific breakthroughs and high-profile clinical setbacks—modern research now focuses on designing molecules that preserve the therapeutic potential of ECS modulation while minimizing central nervous system (CNS)-related toxicity. This new generation of ECS-targeted therapeutics emphasizes receptor selectivity, biased signaling, and peripheral restriction, aiming to deliver efficacy without psychoactive compromise ⁴⁴⁻⁴⁵.

One promising innovation involves the development of allosteric modulators, which bind to sites distinct from the receptor's active (orthosteric) site. Rather than fully activating or blocking the receptor, these modulators fine-tune receptor responses, enhancing or diminishing endogenous signaling in a controlled manner. Such nuanced regulation provides a “dial rather than a switch” approach—offering therapeutic precision while reducing side effects associated with complete receptor activation or inhibition ⁴⁶⁻⁴⁷.

Another emerging avenue is the creation of peripherally acting CB1 antagonists, designed to target metabolic pathways in peripheral organs such as the liver, pancreas, and adipose tissue, without crossing the blood–brain barrier. These compounds hold particular promise in the treatment of obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD)—conditions strongly linked to ECS dysregulation—while avoiding the psychiatric complications that doomed earlier centrally acting agents like rimonabant ⁴⁸.

Furthermore, the exploration of dual-acting ligands—agents capable of simultaneously targeting CB2 receptors and nuclear receptors like PPAR γ (peroxisome proliferator-activated receptor gamma)—represents a cutting-edge strategy for achieving synergistic anti-inflammatory and metabolic benefits. Such dual modulation could be especially beneficial in disorders where inflammation and metabolic dysfunction intersect, such as atherosclerosis and metabolic syndrome (Table 1) ⁴⁹.

In parallel, enzyme inhibitors targeting FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase) are gaining traction as subtler alternatives to direct receptor agonists. By enhancing endogenous cannabinoid levels rather than externally stimulating receptors, these inhibitors preserve the body's natural control over ECS tone. This approach provides a more physiologically balanced form of modulation, with fewer psychotropic or tolerance-related issues ⁵⁰.

Looking ahead, the integration of pharmacogenomics and multi-omics approaches is expected to revolutionize cannabinoid-based therapy. Genetic variations influencing receptor expression, endocannabinoid metabolism, and drug clearance can significantly affect individual treatment responses. By identifying these genetic and molecular determinants, future therapies could be personalized, allowing clinicians to tailor cannabinoid treatments based on a patient's unique biological profile—maximizing efficacy while minimizing adverse reactions

51-52.

Collectively, these emerging strategies reflect a shift from crude receptor targeting toward precision cannabinoid pharmacology—a new era defined by selectivity, safety, and personalization.

7. Conclusion

The endocannabinoid system (ECS) sits at the intersection of neuroscience, immunology, and metabolic regulation, embodying both vast therapeutic promise and significant pharmacological complexity. Over the past few decades, research into the ECS has reshaped our understanding of human physiology, revealing a multifaceted system capable of influencing pain perception, emotional regulation, immune function, and energy metabolism. Yet, with this potential comes a clear warning: manipulating such a powerful homeostatic network demands careful and precise control.

While ECS modulation has demonstrated remarkable benefits in conditions ranging from chronic pain and epilepsy to inflammation and neurodegeneration, the clinical pitfalls—most notably psychotropic effects, tolerance, dependence, and metabolic unpredictability—highlight the need for next-generation, targeted pharmacological approaches. Future therapeutic success will depend on the development of agents that preserve the ECS's beneficial effects while eliminating its central liabilities.

Advances in molecular modeling, receptor biology, and personalized medicine are paving the way for this evolution. The combination of allosteric modulation, peripheral restriction, and pharmacogenomic guidance holds the potential to transform cannabinoid therapy from a field overshadowed by controversy into one defined by scientific precision and clinical reliability.

Once dismissed as a mere byproduct of cannabis research, the ECS has now emerged as one of the most dynamic and promising frontiers in modern pharmacology. Its study continues to challenge our understanding of the fine line between therapy and toxicity—offering a powerful reminder that in biology, as in medicine, balance is everything.

Figure 1. Schematic overview of the Endocannabinoid System




Table 1. Major Endocannabinoid Targets and Their Pharmacological Roles

| Component | Localization | Function | Therapeutic Potential | Clinical Limitation | Reference |
|--------------|--|---------------------------------------|-------------------------------------|------------------------------------|-----------|
| CB1 receptor | CNS (hippocampus, cerebellum, basal ganglia) | Inhibits neurotransmitter release | Analgesia, appetite control | Psychoactive, cognitive impairment | 53 |
| CB2 receptor | Immune cells, spleen, periphery | Modulates inflammation | Anti-inflammatory, neuroprotective | Limited CNS penetration | 54 |
| FAAH | Brain, liver | Degrades anandamide | Anxiety, pain control | Off-target inhibition | 55 |
| MAGL | Brain, adipose tissue | Degrades 2-AG | Analgesia, anti-inflammatory | Tolerance, lipid dysregulation | 56 |
| TRPV1 | Sensory neurons | Mediates pain and temperature | Analgesia | Desensitization | 57 |
| GPR55 | CNS and immune cells | Modulates vascular tone, inflammation | Metabolic and inflammatory diseases | Undefined selectivity | 58 |

Reference

1. Gaoni, Y., & Mechoulam, R. (1964). Isolation, structure and partial synthesis of an active constituent of hashish. *Journal of the American Chemical Society*, 86(8), 1646–1647. <https://doi.org/10.1021/ja01062a046>
2. Howlett, A. C., Johnson, M. R., Melvin, L. S., & Milne, G. M. (1988). Nonclassical cannabinoid analgesics inhibit adenylate cyclase: Development of a cannabinoid receptor model. *Molecular Pharmacology*, 33(3), 297–302.
3. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature*, 346(6284), 561–564. <https://doi.org/10.1038/346561a0>
4. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science*, 258(5090), 1946–1949. <https://doi.org/10.1126/science.1470919>
5. Munro, S. K., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. *Nature*, 365(6441), 61–65. <https://doi.org/10.1038/365061a0>
6. Hanus, L., Gopher, A., Almog, S., & Mechoulam, R. (1993). Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. *Journal of Medicinal Chemistry*, 36(20), 3032–3034.
7. Sugiura, T., Kondo, S., Sukagawa, A., et al. (1995). 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. *Biochemical and Biophysical Research Communications*, 215(1), 89–97.
8. Mechoulam, R., Ben-Shabat, S., Hanus, L., et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochemical Pharmacology*, 50(1), 83–90.
9. Zhang, S. Y., Bridges, D., Gigorenko, E., McCloud, S., Boon, A., Hampson, R. E., & Deadwyler, S. A. (2005). Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. *Neuropharmacology*, 48(7), 1086–1096.
10. Hohmann, A. G., & Herkenham, M. (1999). Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study. *Neuroscience*, 90(3), 923–931.
11. Farquhar-Smith, W. P., Egertova, M., Bradbury, E. J., McMahon, S. B., Rice, A. S., & Elphick, M. R. (2000). Cannabinoid CB1 receptor expression in rat spinal cord. *Molecular and Cellular Neuroscience*, 15(6), 510–521.

12. Ahluwalia, J., Urban, L., Capogna, M., Bevan, S., & Nagy, I. (2000). Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. *Neuroscience*, *100*(3), 685–688.
13. Iversen, L., & Chapman, V. (2002). Cannabinoids: A real prospect for pain relief? *Current Opinion in Pharmacology*, *2*(1), 50–55.
14. Malan, T. P., Ibrahim, M. M., Deng, H., Liu, Q., Mata, H. P., Vanderah, T., Porreca, F., & Makriyannis, A. (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. *Pain*, *93*(3), 239–245.
15. Fride, E., & Shohami, E. (2002). The endocannabinoid system: Function in survival of the embryo, the newborn and the neuron. *NeuroReport*, *13*(15), 1833–1841.
16. Fride, E., Ginzburg, Y., Breuer, A., Bisogno, T., Di Marzo, V., & Mechoulam, R. (2001). Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. *European Journal of Pharmacology*, *419*(2–3), 207–214.
17. Berrendero, F., Sepe, N., Ramos, J. A., Di Marzo, V., & Fernández-Ruiz, J. J. (1999). Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain. *Synapse*, *33*(3), 181–191.
18. Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990). Cannabinoid receptor localization in brain. *Proceedings of the National Academy of Sciences*, *87*(5), 1932–1936.
19. Glass, M., Dragunow, M., & Faull, R. L. (1997). Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience*, *77*(2), 299–318.
20. Katona, I., Rancz, E. A., Acsady, L., Ledent, C., Mackie, K., Hajos, N., & Freund, T. F. (2001). Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. *Journal of Neuroscience*, *21*(23), 9506–9518.
21. Arévalo, C., de Miguel, R., & Hernández-Tristán, R. (2001). Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. *Pharmacology Biochemistry and Behavior*, *70*(1), 123–131.
22. Rodríguez de Fonseca, F., Carrera, M. R. A., Navarro, M., Koob, G. F., & Weiss, F. (1997). Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. *Science*, *276*(5321), 2050–2054
23. Martin, M., Ledent, C., Parmentier, M., Maldonado, R., & Valverde, O. (2002). Involvement of CB1 cannabinoid receptors in emotional behaviour. *Psychopharmacology*, *159*(4), 379–387
24. Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002). The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. *European Journal of Neuroscience*, *16*(7), 1395–1398
25. Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., Di Marzo, V., & Lutz, B.

- (2002). The endogenous cannabinoid system controls extinction of aversive memories. *Nature*, 418(6897), 530–534
26. Di Carlo, G., & Izzo, A. A. (2003). Cannabinoids for gastrointestinal diseases: Potential therapeutic applications. *Expert Opinion on Investigational Drugs*, 12(1), 39–49
27. Van Sickle, M. D., Oland, L. D., Ho, W., Hillard, C. J., Mackie, K., Davison, J. S., Sharkey, K. A., & Cannabinoids. (2001). Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. *Gastroenterology*, 121(4), 767–774
28. Darmani, N. A., Izzo, A. A., Degenhardt, B., Valenti, M., Scaglione, G., Capasso, R., Sorrentini, I., & Di Marzo, V. (2005). Implication of the cannabimimetic compound, N-palmitoylethanolamine, in inflammatory and neuropathic conditions: A review of preclinical data and first human studies. *Neuropharmacology*, 48(8), 1154–1163
29. Dewey, W. L. (1986). Cannabinoid pharmacology. *Pharmacological Reviews*, 38(2), 151–178
30. Lake, K. D., Compton, D. R., Varga, K., Martin, B. R., & Kunos, G. (1997). Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. *Journal of Pharmacology and Experimental Therapeutics*, 281(3), 1030–1037
31. Varga, K., Lake, K. D., Martin, B. R., & Kunos, G. (1995). Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. *European Journal of Pharmacology*, 278(3), 279–283
32. Jarai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., Razdan, R. K., Zimmer, A., & Kunos, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. *Proceedings of the National Academy of Sciences*, 96(24), 14136–14141
33. Pertwee, R. G., Thomas, A., Stevenson, L. A., Maor, Y., & Mechoulam, R. (2005). (–)-7-hydroxy-4'-dimethylheptylcannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens in a cannabidiol-sensitive manner. *Neuropharmacology*, 48(8), 1139–1146
34. Potter, D. (2004). Growth and morphology of medicinal cannabis. In G. W. Guy, B. A. Whittle, & P. J. Robson (Eds.), *The medicinal uses of cannabis and cannabinoids* (pp. 17–54). London: Pharmaceutical Press.
35. Grant, I., Gonzalez, R., Carey, C., Natarajan, L., & Wolfson, T. (2003). Non-acute (residual) neurocognitive effects of cannabis use: A meta-analysis study. *Journal of the International Neuropsychological Society*, 9(5), 679–689
36. Cabral, G. A., & Dove Pettit, D. A. (1998). Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease. *Journal of Neuroimmunology*, 83(1–2), 116–123

37. Peterson, P. K., Gekker, G., Hu, S., Cabral, G., & Lokensgard, J. R. (2004). Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures. *Journal of Neuroimmunology*, 147(1–2), 123–126
38. Robson, P. (2001). Therapeutic aspects of cannabis and cannabinoids. *British Journal of Psychiatry*, 178(2), 107–115
39. Walsh, D., Nelson, K. A., & Mahmoud, F. A. (2003). Established and potential therapeutic applications of cannabinoids in oncology. *Supportive Care in Cancer*, 11(3), 137–143
40. Abrams, D. I., Hilton, J. F., Leiser, R. J., et al. (2003). Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. *Annals of Internal Medicine*, 139(4), 258–266
41. Scallet, A. C. (1991). Neurotoxicology of cannabis and THC: A review of chronic exposure studies in animals. *Pharmacology Biochemistry and Behavior*, 40(3), 671–676
42. Chan, G. C. K., Hinds, T. R., Impey, S., & Storm, D. R. (1998). Hippocampal neurotoxicity of delta-9-tetrahydrocannabinol. *Journal of Neuroscience*, 18(14), 5322–5332
43. Ameri, A. (1999). The effects of cannabinoids on the brain. *Progress in Neurobiology*, 58(4), 315–348
44. Fried, P. A., O’Connell, C. M., & Watkinson, B. (1992). Sixty- and seventy-two-month follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol: Cognitive and language assessment. *Journal of Developmental & Behavioral Pediatrics*, 13(6), 383–391
45. Fried, P. A., Watkinson, B., & Siegel, L. S. (1997). Reading and language in 9- to 12-year-olds prenatally exposed to cigarettes and marijuana. *Neurotoxicology and Teratology*, 19(3), 171–183
46. Goldschmidt, L., Richardson, G. A., Cornelius, M. D., & Day, N. L. (2004). Prenatal marijuana and alcohol exposure and academic achievement at age 10. *Neurotoxicology and Teratology*, 26(4), 521–532
47. Pedersen, W., Mastekaasa, A., & Wichstrom, L. (2001). Conduct problems and early cannabis initiation: A longitudinal study of gender differences. *Addiction*, 96(3), 415–431
48. Maldonado, R., & Rodríguez de Fonseca, F. (2002). Cannabinoid addiction: Behavioral models and neural correlates. *Journal of Neuroscience*, 22(9), 3326–3331
49. Budney, A. J., Novy, P. L., & Hughes, J. R. (1999). Marijuana withdrawal among adults seeking treatment for marijuana dependence. *Addiction*, 94(9), 1311–1322
50. Kouri, E. M., & Pope, H. G. Jr. (2000). Abstinence symptoms during withdrawal from chronic marijuana use. *Experimental and Clinical Psychopharmacology*, 8(4), 483–492

51. Budney, A. J., Hughes, J. R., Moore, B. A., & Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. *American Journal of Psychiatry*, 161(11), 1967–1977
52. House of Lords Select Committee on Science and Technology. (1998). *Cannabis: The scientific and medicinal evidence* (Ninth Report). London: Stationery Office.
53. Canadian Senate Special Committee on Illegal Drugs. (2002). *Cannabis: Our position for a Canadian public policy*. Ottawa: Parliament of Canada. Retrieved from <https://www.parl.gc.ca/>
54. National Academy of Sciences, Institute of Medicine. (1999). *Marijuana and medicine: Assessing the science base*. Washington, DC: National Academy Press.
55. Guy, G. W., Whittle, B. A., & Robson, P. J. (2004). *The medicinal uses of cannabis and cannabinoids*. London: Pharmaceutical Press.
56. Noyes, R. Jr., Brunk, S. F., Baram, D. A., & Canter, A. (1975). Analgesic effect of delta-9-tetrahydrocannabinol. *Journal of Clinical Pharmacology*, 15(2–3), 139–143
57. Noyes, R. Jr., Brunk, S. F., Avery, D. H., & Canter, A. (1975). The analgesic properties of delta-9-tetrahydrocannabinol and codeine. *Clinical Pharmacology & Therapeutics*, 18(1), 84–89. <https://pubmed.ncbi.nlm.nih.gov/50159/>
58. Jain, A. K., Ryan, J. R., McMahon, F. G., & Smith, G. (1981). Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. *Journal of Clinical Pharmacology*, 21(S2), 320S–336S. <https://pubmed.ncbi.nlm.nih.gov/7028791/>